

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5158245

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS
CONVEYING PARTY DATA	
Name	Execution Date
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT	09/21/2018
RECEIVING PARTY DATA	
Name:	TRIS PHARMA, INC.
Street Address:	2033 ROUTE 130
City:	MONMOUTH JUNCTION
State/Country:	NEW JERSEY
Postal Code:	08852
PROPERTY NUMBERS Total: 53	
Property Type	Number
Patent Number:	8062667
Patent Number:	8337890
Patent Number:	8202537
Patent Number:	8491935
Patent Number:	8597684
Patent Number:	8790700
Patent Number:	8747902
Patent Number:	8883217
Patent Number:	9522191
Patent Number:	9198864
Patent Number:	9549989
Patent Number:	9675703
Patent Number:	9675704
Patent Number:	8287848
Patent Number:	8512688
Patent Number:	8202542
Patent Number:	8623409
Patent Number:	8287903
Patent Number:	8465765
Patent Number:	8563033

PATENT

Property Type	Number
Patent Number:	8778390
Patent Number:	8956649
Patent Number:	9040083
Patent Number:	6436430
Patent Number:	6057289
Patent Number:	8999386
Patent Number:	9180100
Patent Number:	9295642
Patent Number:	9545399
Patent Number:	9180104
Patent Number:	9408823
Application Number:	15383474
Application Number:	15200617
Application Number:	15619637
Application Number:	15380153
Application Number:	14679438
Application Number:	14679427
Application Number:	14090274
Application Number:	15215276
Application Number:	15244430
Application Number:	15009468
Application Number:	15009480
Application Number:	15491547
Application Number:	15258695
Application Number:	15258700
Application Number:	14677073
Application Number:	15075697
Application Number:	14829952
Application Number:	14830040
Application Number:	14829971
Application Number:	15593506
Application Number:	15482201
Application Number:	62487837

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-318-6532

Email: alanagramer@paulhastings.com
Correspondent Name: ALANA GRAMER
Address Line 1: C/O PAUL HASTINGS LLP
Address Line 2: 200 PARK AVENUE
Address Line 4: NEW YORK, NEW YORK 10166

NAME OF SUBMITTER:	ALANA GRAMER
---------------------------	--------------

SIGNATURE:	/s/ AG
-------------------	--------

DATE SIGNED:	09/25/2018
---------------------	------------

Total Attachments: 17

source=Tris -Patent Release (Executed)#page1.tif
source=Tris -Patent Release (Executed)#page2.tif
source=Tris -Patent Release (Executed)#page3.tif
source=Tris -Patent Release (Executed)#page4.tif
source=Tris -Patent Release (Executed)#page5.tif
source=Tris -Patent Release (Executed)#page6.tif
source=Tris -Patent Release (Executed)#page7.tif
source=Tris -Patent Release (Executed)#page8.tif
source=Tris -Patent Release (Executed)#page9.tif
source=Tris -Patent Release (Executed)#page10.tif
source=Tris -Patent Release (Executed)#page11.tif
source=Tris -Patent Release (Executed)#page12.tif
source=Tris -Patent Release (Executed)#page13.tif
source=Tris -Patent Release (Executed)#page14.tif
source=Tris -Patent Release (Executed)#page15.tif
source=Tris -Patent Release (Executed)#page16.tif
source=Tris -Patent Release (Executed)#page17.tif

NOTICE OF RELEASE OF
SECURITY INTEREST IN PATENTS
SEPTEMBER 21, 2018

WHEREAS, pursuant to that certain Patent Security Agreement, dated as of August 31, 2017 and recorded in the United States Patent and Trademark Office on September 5, 2017 at Reel 043761, Frame 0389 (the “**Patent Security Agreement**”), each entity listed on the signature pages thereto (each a “**Grantor**” and, collectively, the “**Grantors**”) pledged and granted to JPMORGAN CHASE BANK, N.A., as Administrative Agent (the “**Administrative Agent**”), for the benefit of the Secured Parties, a lien on and security interest in and to all of its right, title and interest in, to and under all Patents of the Grantor listed on Schedule I hereto and all proceeds of any and all of the foregoing (collectively, the “**Patent Collateral**”);

WHEREAS, reference is made to that certain Credit Agreement dated as of August 31, 2017 (as amended, restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), among Tris Pharma, Inc., a New Jersey corporation (the “**Company**”), the other parties party thereto and the Administrative Agent, in its capacity as administrative agent for the lenders party thereto;

WHEREAS, pursuant to the Payoff Letter, dated as of August [29], 2018, by and among the Administrative Agent, the Company and the Administrative Agent, the Company has requested and the Administrative Agent has agreed to procure, execute and deliver to the Company, at the expense of the Company, this Notice of Release of Security Interest in Patents confirming and carrying out the release and discharge of the Secured Parties’ security interest in the Patent Collateral; and

WHEREAS, the Administrative Agent wishes to terminate and release its security interest in the Patent Collateral.

NOW THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent does hereby agree as follows:

1. Release. As of the date first set forth above, the Administrative Agent, on behalf of itself and the Secured Parties (as defined in the Credit Agreement), hereby (i) releases and terminates in its entirety its lien on and security interest in the Patent Collateral, and (ii) discharges, quit claims, and relinquishes unto each Grantor, as applicable, and re-assigns to each Grantor, as applicable, any and all right, title and interest it may have in, to, or under the Patent Collateral of such Grantor.


2. Governing Law. This Notice of Release of Security Interest in Patents shall be governed by and construed and interpreted in accordance with the laws of the State of New York.

3. Definitions. Capitalized terms used herein and not defined shall have the respective meaning ascribed to such terms in the applicable Patent Security Agreement.

[Signature Page Follows]

IN WITNESS WHEREOF, the Administrative Agent has caused this Notice of Release of Security Interest in Patents to be duly executed as of the date first set forth above.

JPMORGAN CHASE BANK, N.A.
as Administrative Agent

By: 
Name: Erica Cross
Title: Authorized Officer

SCHEDULE I

**Grantor: Tris Pharma, Inc.
Registered Patents and Patent Applications**

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	22-Nov-11	8062667
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	25-Dec-12	8337890
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	19-Jun-12	8202537
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	23-Jul-13	8491935
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	3-Dec-13	8597684
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	29-Jul-14	8790700
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	10-Jun-14	8747902

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	11-Nov-14	8883217
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	20-Dec-16	9522191
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	1-Dec-15	9198864
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	24-Jan-17	9549989
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	13-Jun-17	9675703
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Issued	13-Jun-17	9675704
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Australia	Issued	Dec 24, 2013	2007227569
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Canada	Issued	Feb 3, 2015	2,645,855

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	China	Issued	11-Jan-12	20078000920
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Israel	Issued	Oct 1, 2014	194042
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Japan	Issued	12-Feb-14	5479086
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Korea	Issued	Feb 13, 2015	10-1495146
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Russian Federation	Issued	10-Dec-11	2435569
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	European Patent Office	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Belgium	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Denmark	Issued	14-Dec-11	2018160

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	France	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Germany	Issued	14-Dec-11	602007019356.7
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Ireland	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Netherlands	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Spain	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Sweden	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Switzerland	Issued	14-Dec-11	2018160
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United Kingdom	Issued	14-Dec-11	2018160

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	China	Issued	18-Jun-14	CN 102488652 B
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	European Patent Office	Issued	3-Oct-12	2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Belgium	Issued	3-Oct-12	EP2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Denmark	Issued	3-Oct-12	2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	France	Issued	3-Oct-12	EP2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Germany	Issued	3-Oct-12	602007025954.1
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Ireland	Issued	3-Oct-12	EP2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Netherlands	Issued	3-Oct-12	EP2428205

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Spain	Issued	3-Oct-12	EP2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Sweden	Issued	3-Oct-12	EP2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Switzerland	Issued	3-Oct-12	EP2428205
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United Kingdom	Issued	3-Oct-12	EP2428205
FORMULATIONS CONTAINING AN IONIC MINERAL-ION EXCHANGE RESIN COMPLEX AND USES THEREOF	United States of America	Issued	16-Oct-12	8287848
FORMULATIONS CONTAINING AN IONIC MINERAL-ION EXCHANGE RESIN COMPLEX AND USES THEREOF	United States of America	Issued	20-Aug-13	8512688
ABUSE RESISTANT OPIOID DRUG-ION EXCHANGE RESIN COMPLEXES HAVING HYBRID COATINGS	United States of America	Issued	19-Jun-12	8202542
NOVEL CLONIDINE FORMULATION	United States of America	Issued	7-Jan-14	8623409

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Issued	16-Oct-12	8287903
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Issued	18-Jun-13	8465765
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Issued	22-Oct-13	8563033
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Issued	15-Jul-14	8778390
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Issued	Feb 17, 2015	8,956,649
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Issued	May 26, 2015	9,040,083
Self Emulsifying Composition s for Drugs Poorly Soluble in Water	United States of America	Issued	20-Aug-02	6436430

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN IN ASSOCIATION WITH A CARRIER IN A SELF- EMULSIFYING DRUG DELIVERY SYSTEM	United States of America	Issued	2-May-00	6057289
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	United States of America	Issued	Apr 7, 2015	8,999,386
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	United States of America	Issued	21-Oct-15	9180100
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	United States of America	Issued	29-Mar-16	9295642
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	United States of America	Issued	17-Jan-17	9545399
Benzonatate Modified Release Solid Tablets and Capsules	European Patent Office	Issued	19-Apr-17	2968151
Benzonatate Modified Release Solid Tablets and Capsules	Belgium	Issued	19-Apr-17	2968151
Benzonatate Modified Release Solid Tablets and Capsules	Switzerland	Issued	19-Apr-17	2968151
Benzonatate Modified Release Solid Tablets and Capsules	Germany	Issued	19-Apr-17	2968151
Benzonatate Modified Release Solid Tablets and Capsules	France	Issued	19-Apr-17	2968151
Benzonatate Modified Release Solid Tablets and Capsules	Ireland	Issued	19-Apr-17	2968151

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
Benzonatate Modified Release Solid Tablets and Capsules	United Kingdom	Issued	19-Apr-17	2968151
Benzonatate Modified Release Solid Tablets and Capsules	United States of America	Issued	10-Nov-15	9180104
Benzonatate Modified Release Solid Tablets and Capsules	United States of America	Issued	9-Aug-16	9408823
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Published	19-Dec-16	15383474
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	United States of America	Published	1-Jul-16	15/200,617
Unpublished - Confidential	United States of America	Pending	12-Jun-17	15/619,637
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	Brazil	Published	15-Mar-07	PI07096062
MODIFIED RELEASE FORMATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES	India	Published	16-Oct-08	08703DELNP08
Unpublished - Confidential	United States of America	Pending	15-Dec-16	15380153
Unpublished - Confidential	United States of America	Pending	6-Apr-15	14679438

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
Unpublished - Confidential	United States of America	Pending	6-Apr-15	14679427
NOVEL CLONIDINE FORMULATION	United States of America	Published	26-Nov-13	14090274
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Published	20-Jul-16	15215276
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	United States of America	Published	23-Aug-16	15244430
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	Australia	Pending	15-Feb-11	2017202955
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	Brazil	Pending	15-Feb-11	BR1120130205377
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	Canada	Pending	15-Feb-11	2825991
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	European Patent Office	Published	15-Feb-11	11705375

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT	Israel	Pending	15-Feb-11	227734
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	Australia	Pending	14-Aug-13	2013302657
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	Brazil	Pending	14-Aug-13	BR112015003120- 0
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	Canada	Pending	14-Aug-13	2880456
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	European Patent Office	Published	14-Aug-13	13 752 782.6
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	Israel	Pending	14-Aug-13	236847
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	United States of America	Pending	28-Jan-16	15/009,468
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	United States of America	Allowed, Issue Fee paid	28-Jan-16	15/009,480
METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET	United States of America	Allowed, Issue Fee paid (unpublished)	19-Apr-17	15491547
Unpublished - Confidential	United States of America	Pending	7-Sep-16	15258695
Unpublished - Confidential	United States of America	Pending	7-Sep-16	15258700
Unpublished - Confidential	United States of America	Pending	Apr 2, 2015	14677073

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
Benzonatate Modified Release Solid Tablets and Capsules	Australia	Pending	Mar 11, 2014	2014240988
Benzonatate Modified Release Solid Tablets and Capsules	Brazil	Pending	Mar 11, 2014	BR112015021403-7
Benzonatate Modified Release Solid Tablets and Capsules	Canada	Pending	Mar 11, 2014	2904045
Benzonatate Modified Release Solid Tablets and Capsules	China	Published	Mar 11, 2014	201480014194.9
Benzonatate Modified Release Solid Tablets and Capsules	Indonesia	Published	Mar 11, 2014	P00201505946
Benzonatate Modified Release Solid Tablets and Capsules	Israel	Pending	Mar 11, 2014	241533
Benzonatate Modified Release Solid Tablets and Capsules	Japan	Pending	Mar 11, 2014	2016-501151
Benzonatate Modified Release Solid Tablets and Capsules	Mexico	Pending	Mar 11, 2014	MX/A/2015/012092
Benzonatate Modified Release Solid Tablets and Capsules	Republic of Korea	Pending	Mar 11, 2014	10-2015-7023709
Benzonatate Modified Release Solid Tablets and Capsules	Russian Federation	Pending	Mar 11, 2014	2015143515
Benzonatate Modified Release Solid Tablets and Capsules	Thailand	Pending	Mar 11, 2014	1501005371
Benzonatate Modified Release Solid Tablets and Capsules	United States of America	Published	March 21, 2016	15075697
Unpublished - Confidential	United States of America	Pending	19-Aug-15	14/829,952

Patent Description	Country	Status	Registration/ Application Date	Registration/ Application Number
Unpublished - Confidential	United States of America	Pending	19-Aug-15	14/830,040
Unpublished - Confidential	United States of America	Pending	19-Aug-15	14/829,971
Unpublished - Confidential	United States of America	Pending	12-May-17	15/593,506
Unpublished - Confidential	United States of America	Pending	7-Apr-17	15482201
Unpublished - Confidential	United States of America	Pending	20-Apr-17	62487837

Included in the above table but In name of Pharmasolutions, Inc. (merged into Tris Pharma, Inc.) but patents not officially retitled

Patent Description	Country		Registration/ Application Date	Registration/ Application Number
Self Emulsifying Composition s for Drugs Poorly Soluble in Water	United States of America	Issued	20-Aug-02	6436430
PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN IN ASSOCIATION WITH A CARRIER IN A SELF-EMULSIFYING DRUG DELIVERY SYSTEM	United States of America	Issued	2-May-00	6057289